Home / Research / Department of
Molecular Medicine

Laboratory of Organ Regeneration

Head
Christodoulos
Xinaris
Research Director
christodoulos.xinaris@marionegri.it
Senior Advisor
No items found.

The laboratory of Organ Regeneration is focused on developing next-generation human disease models and regenerative medicine therapies for chronic diseases and acute tissue injuries.

The laboratory's research incorporates organoid, tissue on chip and tissue engineering approaches, as well as nanomedicines and in vivo animal models.

RESEARCH AREAS

Engineering 3D human organoids and tissues for disease modelling, drug testing, and replacement therapies

Complex human 3D tissues are engineered with 3D culture systems and 3D bioprinting technologies using patients’ own cells derived from biopsies, or with induced pluripotent stem cells (iPSCs). These miniature replicas of organs (organoids) or tissues are used to model human diseases, test drugs, and study the development of human tissue in vitro. Transplantable bio-artificial tissues are also optimised for the treatment of renal anaemia.

Modulating thyroid hormone signalling to regenerate damaged organs

In this research line we study the role of thyroid hormone (TH) signalling in organ repair/regeneration during chronic stress (i.e., diabetic kidney, heart and pancreas) and after acute injury (i.e., acute renal failure and myocardial infarction). The methodology incorporates developmental biology principles and nanomedicine approaches to target and deliver TH to injured cells in order to spatiotemporally coordinate tissue regeneration.

Developing an organ on chip to model the functions of the glomerulus (the kidney’s filtering unit) in vitro

The planned methodology aims to mimic the essential physiological and mechanical features of the human glomerulus. It will be used to (i) study cellular pathophysiological pathways in response to kidney injuries; (ii) model rare kidney diseases; and (iii) test drug toxicity and efficacy in a personalised manner.

Treatment of autosomal polycistic kidney disease (ADPKD) using nanomedicine

In this line of research we work to develop an innovative nanomedicine approach to effectively and safely release L-thyroxine (T4) into the kidney, a hormone produced by the thyroid, usually reduced in patients with chronic kidney disease. Previous laboratory studies have shown that treatment with T4 can slow the progression of the disease in preclinical models, but it is necessary to find the right way to transport it and selectively release it into the kidney, avoiding unwanted effects. This research aims to develop a safe, efficient and easy-to-use method for treating ADPKD and generate important knowledge for understanding this disease.

Head Unit
No items found.
Staff
Alice
Del Vecchio
Researcher
alice.delvecchio@marionegri.it
Angelo Michele
Lavecchia
Researcher
angelomichele.lavecchia@marionegri.it
Benedetta
Petracca
Researcher
benedetta.petracca@marionegri.it
Eleonora
Fiorentini
Researcher
eleonora.fiorentini@marionegri.it
Laura
Locatelli
Researcher
laura.locatelli@marionegri.it
Melissa
Balsamo
Researcher
melissa.balsamo@marionegri.it
This is some text inside of a div block.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Codice:

International Consensus on Cardiopulmonary Resuscitation.

1205
Non ci sono pubblicazioni selezionate al momento.
Head
Christodoulos
Xinaris
Research Director
christodoulos.xinaris@marionegri.it
Senior Advisor
No items found.

Related Laboratories

Tieniti aggiornato sulle novità dell'Istituto Mario Negri. 

Iscriviti alla newsletter
Pagina Italiano